BeOne Medicines (BEIGF) Property, Plant & Equipment (Net) Growth (3y) (2018 - 2026)
Analysis
BeOne Medicines (BEIGF) Property, Plant & Equipment (Net) Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.47 Bn | 624.71 Bn | 17.26 Bn | 4.65% |
| 2 | AbbVie | 439.99 Bn | 433.42 Bn | 12.70 Bn | 5.45% |
| 3 | Merck | 365.45 Bn | 358.31 Bn | 12.21 Bn | 5.00% |
| 4 | Novartis Ag | 266.57 Bn | 258.88 Bn | 11.24 Bn | -0.43% |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | 2.85% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 3.06% |
| 7 | Revolution Medicines | 44.23 Bn | 44.23 Bn | - | - |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | -1.81% |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn | 27.15% |
| 10 | BeOne Medicines | 2.48 Bn | -2.62 Bn | 1.53 Bn | 16.78% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 16.78% |
| Mar 31, 2026 | 21.04% |
| Dec 31, 2025 | 24.73% |
| Sep 30, 2025 | 33.65% |
| Jun 30, 2025 | 36.66% |
| Mar 31, 2025 | 36.78% |
| Dec 31, 2024 | 39.01% |
| Sep 30, 2024 | 51.35% |
| Jun 30, 2024 | 56.56% |
| Mar 31, 2024 | 55.94% |
| Dec 31, 2023 | 54.70% |
| Sep 30, 2023 | 59.34% |
| Jun 30, 2023 | 58.72% |
| Mar 31, 2023 | 56.74% |
| Dec 31, 2022 | 51.68% |
| Sep 30, 2022 | 44.40% |
| Jun 30, 2022 | 43.85% |
| Mar 31, 2022 | 46.71% |
| Dec 31, 2021 | 55.24% |
| Sep 30, 2021 | 59.42% |